Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1156

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9C
Chunk 1156
---
6) 

    Michelle
    Yanez, CFO 
    3/25/2024 
     -  
        
     -  
     -  
     -  
     -  
     -  
     150,000 (7) 
    $1.16  
    $1.16 
    $159,750 

    12/6/2024 

     150,000  
    $1.19  
    $1.19  
     99.150 

    (1)
    The
    “Grant Date” represents the date on which the Compensation Committee of the Board took action to grant the applicable
    award.
  
    (2)
    The
    stock awards disclosed in this item consist of options, as issued under our 2022 Omnibus Incentive Plan, which 50% on grant date
    and 50% on the first anniversary of grant date. 
  
    (3)
    The
    stock awards disclosed in this item consist of options, as issued under our 2022 Omnibus Incentive Plan, which 50% six months after
    grant date and 50% on the first anniversary of grant date. 
  
    (4)
    The
    stock awards disclosed in this item consist of options, as issued under our 2022 Omnibus Incentive Plan, which 50% six months after
    grant date and 50% on the first anniversary of grant date.

  (5)
  The
  stock awards disclosed in this item consist of Restricted Stock Units (RSU’s), as issued under our 2022 Omnibus Incentive Plan,
  which vest 50% on February 12, 2025 and 50% on June 6, 2025

  (6)
  Represents
  a cash award that Compensation Committee awarded based on CEO performance

  (7)
  The
  stock awards disclosed in this item consist of options, as issued under our 2022 Omnibus Incentive Plan, which vest 50% on grant date,
  and 50% six months from grant date.

Outstanding
equity awards

The
following table summarizes outstanding unexercised options held by each of our named executive officers, as of December 31, 2024.

    OPTION
    AWARDS 
    STOCK
    AWARDS